Literature DB >> 16261471

Postoperative myasthenic crisis successfully treated with immunoadsorption therapy.

Junko Ishizeki1, Koichi Nishikawa, Fumio Kunimoto, Fumio Goto.   

Abstract

Myasthenia gravis (MG) is an autoimmune disorder characterized by loss of acetylcholine receptors (AChR) due primarily to the production of anti-AChR autoantibodies. We report a case of MG associated with elevated anti-acetylcholine receptor antibody (anti-AChR Ab) and refractory crisis after thymectomy, in which immunoadsorption therapy was used successfully to stabilize myasthenic symptoms and decrease the anti-AChR Ab titer. A 79-year-old woman underwent extended thymectomy under the diagnosis of MG. One day after surgery she suddenly underwent a myasthenic crisis and was successfully resuscitated. Immunoadsorption therapy with a tryptophan-linked polyvinyl alcohol adsorber was performed three times for the purpose of decreasing the anti-AChR antibodies. The anti-AChR Ab titer was reduced by immunoadsorption during each therapy session; however, the level of anti-AChR Ab before immunoadsorption was higher than that of the previous treatment. This case suggests that the absolute serum level of anti-AChR Ab does not always correlate with the severity of the disease. Removal of pathogenic factors, not only anti-AChR Ab but other antibodies with specificities to skeletal muscles or certain components of the complement system, may contribute to effective treatment of myasthenic crisis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16261471     DOI: 10.1007/s00540-005-0335-z

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  9 in total

1.  Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis.

Authors:  Atsushi Watanabe; Toshiaki Watanabe; Takuro Obama; Tohru Mawatari; Hisayoshi Ohsawa; Yasunori Ichimiya; Noriyuki Takahashi; Katsuyuki Kusajima; Tomio Abe
Journal:  J Thorac Cardiovasc Surg       Date:  2004-03       Impact factor: 5.209

2.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

3.  Immunoadsorption therapy for myasthenia gravis.

Authors:  N Shibuya; T Sato; M Osame; T Takegami; S Doi; S Kawanami
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

Review 4.  Myasthenia gravis.

Authors:  D B Drachman
Journal:  N Engl J Med       Date:  1994-06-23       Impact factor: 91.245

5.  Steroid therapy without primary dose escalation for postthymectomy crisis in 2 thymomatous myasthenia gravis patients.

Authors:  Masayoshi Inoue; Kentaro Kimura; Katsuko Hasegawa; Kiyohiro Fujiwara; Katsuhiro Nakagawa; Tsutomu Yasumitsu
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-04

6.  Muscle autoantibodies in subgroups of myasthenia gravis patients.

Authors:  F Romi; G O Skeie; J A Aarli; N E Gilhus
Journal:  J Neurol       Date:  2000-05       Impact factor: 4.849

Review 7.  Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology.

Authors:  Jon M Lindstrom
Journal:  Ann N Y Acad Sci       Date:  2003-09       Impact factor: 5.691

Review 8.  Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets.

Authors:  Angela Vincent; John Bowen; John Newsom-Davis; John McConville
Journal:  Lancet Neurol       Date:  2003-02       Impact factor: 44.182

9.  Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation.

Authors:  D B Drachman; C W Angus; R N Adams; J D Michelson; G J Hoffman
Journal:  N Engl J Med       Date:  1978-05-18       Impact factor: 91.245

  9 in total
  1 in total

1.  Effects of General-epidural Anaesthesia on Haemodynamics in Patients with Myasthenia Gravis.

Authors:  X-Z Liu; C-W Wei; H-Y Wang; Y-H Ge; J Chen; J Wang; Y Zhang
Journal:  West Indian Med J       Date:  2015-01-28       Impact factor: 0.171

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.